vs
Medpace Holdings, Inc.（MEDP）とUbiquiti Inc.（UI）の財務データ比較。上の社名をクリックして会社を切り替えられます
Ubiquiti Inc.の直近四半期売上が大きい（$814.9M vs $708.5M、Medpace Holdings, Inc.の約1.2倍）。Ubiquiti Inc.の純利益率が高く（28.7% vs 19.1%、差は9.6%）。Ubiquiti Inc.の前年同期比売上増加率が高い（35.8% vs 32.0%）。Ubiquiti Inc.の直近四半期フリーキャッシュフローが多い（$260.3M vs $188.1M）。過去8四半期でUbiquiti Inc.の売上複合成長率が高い（28.6% vs 17.7%）
Medpace Holdings, Inc.は米国オハイオ州シンシナティに本社を置くグローバルな臨床研究機関（CRO）で、従業員数は約6,000人です。フルサービス体制を採用し、グローバル中央検査室、画像コアラボ、生物分析検査室サービスを提供するほか、本社敷地内に第I相臨床試験部門を設けています。
Ubiquiti Inc.は2003年に米国カリフォルニア州サンノゼで設立されたテクノロジー企業で、現在はニューヨークに本社を置いています。複数のブランドを展開し、企業および一般家庭向けの有線・無線データ通信機器の製造・販売を事業の柱としています。
MEDP vs UI — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $708.5M | $814.9M |
| 純利益 | $135.1M | $233.6M |
| 粗利率 | — | 45.9% |
| 営業利益率 | 21.6% | 35.9% |
| 純利益率 | 19.1% | 28.7% |
| 売上前年比 | 32.0% | 35.8% |
| 純利益前年比 | 15.5% | 70.8% |
| EPS（希薄化後） | $4.65 | $3.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $708.5M | $814.9M | ||
| Q3 25 | $659.9M | $733.8M | ||
| Q2 25 | $603.3M | $759.2M | ||
| Q1 25 | $558.6M | $664.2M | ||
| Q4 24 | $536.6M | $599.9M | ||
| Q3 24 | $533.3M | $550.3M | ||
| Q2 24 | $528.1M | $507.5M | ||
| Q1 24 | $511.0M | $493.0M |
| Q4 25 | $135.1M | $233.6M | ||
| Q3 25 | $111.1M | $207.9M | ||
| Q2 25 | $90.3M | $266.7M | ||
| Q1 25 | $114.6M | $180.4M | ||
| Q4 24 | $117.0M | $136.8M | ||
| Q3 24 | $96.4M | $128.0M | ||
| Q2 24 | $88.4M | $103.8M | ||
| Q1 24 | $102.6M | $76.3M |
| Q4 25 | — | 45.9% | ||
| Q3 25 | — | 46.0% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | 44.5% | ||
| Q4 24 | — | 41.2% | ||
| Q3 24 | — | 42.1% | ||
| Q2 24 | — | 40.2% | ||
| Q1 24 | — | 35.3% |
| Q4 25 | 21.6% | 35.9% | ||
| Q3 25 | 21.5% | 35.7% | ||
| Q2 25 | 20.9% | 34.4% | ||
| Q1 25 | 20.3% | 34.2% | ||
| Q4 24 | 23.4% | 29.8% | ||
| Q3 24 | 21.1% | 30.7% | ||
| Q2 24 | 19.9% | 27.3% | ||
| Q1 24 | 20.4% | 22.6% |
| Q4 25 | 19.1% | 28.7% | ||
| Q3 25 | 16.8% | 28.3% | ||
| Q2 25 | 15.0% | 35.1% | ||
| Q1 25 | 20.5% | 27.2% | ||
| Q4 24 | 21.8% | 22.8% | ||
| Q3 24 | 18.1% | 23.3% | ||
| Q2 24 | 16.7% | 20.5% | ||
| Q1 24 | 20.1% | 15.5% |
| Q4 25 | $4.65 | $3.86 | ||
| Q3 25 | $3.86 | $3.43 | ||
| Q2 25 | $3.10 | $4.40 | ||
| Q1 25 | $3.67 | $2.98 | ||
| Q4 24 | $3.67 | $2.26 | ||
| Q3 24 | $3.01 | $2.12 | ||
| Q2 24 | $2.75 | $1.72 | ||
| Q1 24 | $3.20 | $1.26 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $497.0M | $302.8M |
| 総負債低いほど良い | — | $47.5M |
| 株主資本純資産 | $459.1M | $1.0B |
| 総資産 | $2.0B | $1.6B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.05× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $497.0M | $302.8M | ||
| Q3 25 | $285.4M | $177.2M | ||
| Q2 25 | $46.3M | $149.7M | ||
| Q1 25 | $441.4M | $151.0M | ||
| Q4 24 | $669.4M | $133.1M | ||
| Q3 24 | $656.9M | $165.2M | ||
| Q2 24 | $510.9M | $126.3M | ||
| Q1 24 | $407.0M | $102.5M |
| Q4 25 | — | $47.5M | ||
| Q3 25 | — | $133.8M | ||
| Q2 25 | — | $250.0M | ||
| Q1 25 | — | $340.0M | ||
| Q4 24 | — | $406.3M | ||
| Q3 24 | — | $552.5M | ||
| Q2 24 | — | $708.1M | ||
| Q1 24 | — | $877.5M |
| Q4 25 | $459.1M | $1.0B | ||
| Q3 25 | $293.6M | $828.4M | ||
| Q2 25 | $172.4M | $668.3M | ||
| Q1 25 | $593.6M | $436.1M | ||
| Q4 24 | $825.5M | $290.4M | ||
| Q3 24 | $881.4M | $188.1M | ||
| Q2 24 | $763.6M | $95.1M | ||
| Q1 24 | $671.5M | $25.9M |
| Q4 25 | $2.0B | $1.6B | ||
| Q3 25 | $1.8B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.1B | $1.2B | ||
| Q2 24 | $1.9B | $1.2B | ||
| Q1 24 | $1.8B | $1.2B |
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 7.45× | ||
| Q1 24 | — | 33.92× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $192.7M | $263.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $188.1M | $260.3M |
| FCFマージンFCF / 売上 | 26.6% | 31.9% |
| 設備投資強度設備投資 / 売上 | 0.6% | 0.4% |
| キャッシュ転換率営業CF / 純利益 | 1.43× | 1.13× |
| 直近12ヶ月FCF直近4四半期 | $681.9M | $699.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $192.7M | $263.9M | ||
| Q3 25 | $246.2M | $198.5M | ||
| Q2 25 | $148.5M | $130.4M | ||
| Q1 25 | $125.8M | $123.6M | ||
| Q4 24 | $190.7M | $152.4M | ||
| Q3 24 | $149.1M | $233.7M | ||
| Q2 24 | $116.4M | $231.4M | ||
| Q1 24 | $152.7M | $163.9M |
| Q4 25 | $188.1M | $260.3M | ||
| Q3 25 | $235.5M | $193.3M | ||
| Q2 25 | $142.4M | $125.2M | ||
| Q1 25 | $115.8M | $120.7M | ||
| Q4 24 | $183.0M | $150.4M | ||
| Q3 24 | $138.5M | $231.1M | ||
| Q2 24 | $103.5M | $229.5M | ||
| Q1 24 | $147.2M | $160.6M |
| Q4 25 | 26.6% | 31.9% | ||
| Q3 25 | 35.7% | 26.3% | ||
| Q2 25 | 23.6% | 16.5% | ||
| Q1 25 | 20.7% | 18.2% | ||
| Q4 24 | 34.1% | 25.1% | ||
| Q3 24 | 26.0% | 42.0% | ||
| Q2 24 | 19.6% | 45.2% | ||
| Q1 24 | 28.8% | 32.6% |
| Q4 25 | 0.6% | 0.4% | ||
| Q3 25 | 1.6% | 0.7% | ||
| Q2 25 | 1.0% | 0.7% | ||
| Q1 25 | 1.8% | 0.4% | ||
| Q4 24 | 1.4% | 0.3% | ||
| Q3 24 | 2.0% | 0.5% | ||
| Q2 24 | 2.4% | 0.4% | ||
| Q1 24 | 1.1% | 0.7% |
| Q4 25 | 1.43× | 1.13× | ||
| Q3 25 | 2.22× | 0.95× | ||
| Q2 25 | 1.65× | 0.49× | ||
| Q1 25 | 1.10× | 0.68× | ||
| Q4 24 | 1.63× | 1.11× | ||
| Q3 24 | 1.55× | 1.83× | ||
| Q2 24 | 1.32× | 2.23× | ||
| Q1 24 | 1.49× | 2.15× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
UI
| Enterprise Technology | $729.0M | 89% |
| Service Provider Technology | $85.9M | 11% |
